“Quick and easy searches through vast databases of cancer patients can save doctors’ time and help pharmaceutical companies find discrete populations of patients for potentially life-saving clinical trials. It’s a solution that can jumpstart research.” -Health IT Answers
Vaccinations and hope are permeating our communities; however, patients are still postponing diagnostic tests and screenings, and researchers are still focusing on combatting COVID-19. To expand patient enrollment in trials and offer them as therapeutic options, we must negate time-consuming and inefficient processes that hindered recruitment efforts in the past.
Before the pandemic, only 5 percent of oncology patients participated in clinical trials. As enrollment in cancer clinical trials picks up momentum, healthcare organizations will require better solutions to make up for time lost during COVID-19. Instead of fumbling with file folders, digging through EHRs, and double-checking with doctors, natural language processing and other AI-related tools are more frequently being used to identify eligible patients for best-fit cancer clinical trials.
Learn more in this article from Health IT Answers and Marie E. Lamont, President and Chief Operating Officer at Inteliquet™, about how we can jumpstart cancer clinical research after COVID-19 with the right technology solutions.